CoChat
Sign Up
Cited by 89Mesenchymal stem cell researchHematopoietic Stem Cell TransplantationPeriodontal Regeneration and Treatments

Multi-Parameter Analysis of Biobanked Human Bone Marrow Stromal Cells Shows Little Influence for Donor Age and Mild Comorbidities on Phenotypic and Functional Properties

Open access
Andrzejewska, Anastazja, Catar, Rusan, Schoon, Janosch, Qazi, Taimoor Hasan, Sass, Frauke Andrea, Jacobi, Dorit, Blankenstein, Antje, Reinke, Simon +15 more·2019·Frontiers in Immunology
DOI 10.3389/fimmu.2019.02474PMC PMC6857652
Open this paper in CoChat — free accountOpen PDF

Abstract

Heterogeneous populations of human bone marrow-derived stromal cells (BMSC) are among the most frequently tested cellular therapeutics to treat degenerative and immune disorders, which occur predominantly in the aging population. Currently, it is unclear, if advanced donor age and commonly associated comorbidities affect the properties of ex vivo-expanded BMSCs. Thus, we stratified cells from adult and elderly donors from our biobank (n=10 and n=13, mean age 38 and 72 years) and compared their phenotypic and functional performance, using multiple assays typically employed as minimal criteria for defining multipotent mesenchymal stromal cells (MSCs). We found that BMSCs from both cohorts meet the MSC standard criteria, exhibiting similar morphology, growth kinetics, gene expression profiles, pro-angiogenic and immunosuppressive potential, and the capacity to differentiate toward adipogenic, chondrogenic and osteogenic lineage. We found no substantial differences between cells from adult and elderly cohorts. As positive controls, we studied the impact of in vitro aging and inflammatory cytokine stimulation. Both conditions clearly affected the cellular properties independent of donor age. We conclude that in vitro aging rather than in vivo donor aging influences BMSC characteristics.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2019.02474

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In vitro aging (expanding or passaging) has shown a stronger impact on MSC phenotypic and functional properties than in vivo aging (donor age).

    “Surprisingly, the in vitro aging (i.e., expanding or passaging) has shown a stronger impact on MSC phenotypic and functional properties than in vivo aging (i.e., donor age) [335].”

    From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [335]

  • Single-cell RNA sequencing enables the distinction of transcription differences in MSCs at the single-cell level, thereby facilitating better resolution of their heterogeneity for precision medicine.

    “Currently, the advent of single-cell RNA sequencing (scRNA-seq) has enabled the distinction of transcription differences in MSCs at the single-cell level, thereby facilitating better resolution of their heterogeneity for precision medicine [335].”

    From Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells (2025) · cites this paper as [335]

    The Materials and Methods section describes RNA sequencing of BMSC samples, and the Results compare gene-expression profiles across donor groups and culture passages. Neither those passages nor the passages retrieved for “single-cell,” “heterogeneity,” and “precision medicine” address whether scRNA-seq resolves transcriptional differences among individual MSCs or supports precision medicine. Page numbers were not available in our copy. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 103 · Cited by 89

Research works printed but not linked: 97

  1. [1]Reinke S Dienelt A Blankenstein A Duda GN Geissler S. Qualifying stem cell sources: how to overcome potential pitfalls in regenerative medicine? J Tissue Eng Regen Med. (2016) 10: 3– 10. 10.1002/term.1923 24919850 · DOI
  2. [2]Moll G Le Blanc K Engineering more efficient multipotent mesenchymal stromal (stem) cells for systemic delivery as cellular therapy. ISBT Sci Ser. (2015) 10: 357– 65. 10.1111/voxs.12133 · DOI
  3. [3]Moll G Geissler S Catar R Ignatowicz L Hoogduijn MJ Strunk D. Cryopreserved or fresh mesenchymal stromal cells: only a matter of taste or key to unleash the full clinical potential of MSC therapy? Adv Exp Med Biol. (2016) 951: 77– 98. 10.1007/978-3-319-45457-3_7 27837556 · DOI
  4. [5]Ketterl N Brachtl G Schuh C Bieback K Schallmoser K Reinisch A. A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance. Stem Cell Res Ther. (2015) 6: 236. 10.1186/s13287-015-0233-8 26620155 PMC4666276 · DOI
  5. [6]Moll G Ignatowicz L Catar R Luecht C Sadeghi B Hamad O. Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua. Stem Cells Dev. (2015) 24: 2269– 79. 10.1089/scd.2015.0120 26192403 · DOI
  6. [7]Oeller M Laner-Plamberger S Hochmann S Ketterl N Feichtner M Brachtl G. Selection of tissue factor-deficient cell transplants as a novel strategy for improving hemocompatibility of human bone marrow stromal cells. Theranostics. (2018) 8: 1421– 34. 10.7150/thno.21906 29507631 PMC5835947 · DOI
  7. [8]Von Bahr L Sundberg B Lonnies L Sander B Karbach H Hagglund H. Long-term complications, immunologic effects, and role of passage for outcome in mesenchymal stromal cell therapy. Biol Blood Marrow Transplant. (2012) 18: 557– 64. 10.1016/j.bbmt.2011.07.023 21820393 · DOI
  8. [9]Moll G Alm JJ Davies LC Von Bahr L Heldring N Stenbeck-Funke L. Do cryopreserved mesenchymal stromal cells display impaired immunomodulatory and therapeutic properties? Stem Cells. (2014) 32: 2430– 42. 10.1002/stem.1729 24805247 PMC4381870 · DOI
  9. [10]Moll G Hult A Von Bahr L Alm JJ Heldring N Hamad OA. Do ABO blood group antigens hamper the therapeutic efficacy of mesenchymal stromal cells? PLoS ONE. (2014) 9: e85040. 10.1371/journal.pone.0085040 24454787 PMC3890285 · DOI
  10. [11]Pumberger M Qazi TH Ehrentraut MC Textor M Kueper J Stoltenburg-Didinger G. Synthetic niche to modulate regenerative potential of MSCs and enhance skeletal muscle regeneration. Biomaterials. (2016) 99: 95– 108. 10.1016/j.biomaterials.2016.05.009 27235995 · DOI
  11. [12]Qazi TH Mooney DJ Duda GN Geissler S. Biomaterials that promote cell-cell interactions enhance the paracrine function of MSCs. Biomaterials. (2017) 140: 103– 14. 10.1016/j.biomaterials.2017.06.019 28644976 · DOI
  12. [13]Caplan H Olson SD Kumar A George M Prabhakara KS Wenzel P. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Front Immunol. (2019) 10: 1645. 10.3389/fimmu.2019.01645 31417542 PMC6685059 · DOI
  13. [14]Rubin H. Cell aging in vivo and in vitro. Mech Ageing Dev. (1997) 98: 1– 35. 10.1016/S0047-6374(97)00067-5 9255755 · DOI
  14. [15]Dimmeler S Leri A. Aging and disease as modifiers of efficacy of cell therapy. Circ Res. (2008) 102: 1319– 30. 10.1161/CIRCRESAHA.108.175943 18535269 PMC2728476 · DOI · Paper page
  15. [16]Wagner W Bork S Lepperdinger G Joussen S Ma N Strunk D. How to track cellular aging of mesenchymal stromal cells? Aging. (2010) 2: 224– 30. 10.18632/aging.100136 20453259 PMC2881510 · DOI
  16. [17]Baker N Boyette LB Tuan RS. Characterization of bone marrow-derived mesenchymal stem cells in aging. Bone. (2015) 70: 37– 47. 10.1016/j.bone.2014.10.014 25445445 · DOI
  17. [18]Efimenko AY Kochegura TN Akopyan ZA Parfyonova YV. Autologous stem cell therapy: how aging and chronic diseases affect stem and progenitor cells. Biores Open Access. (2015) 4: 26– 38. 10.1089/biores.2014.0042 26309780 PMC4497652 · DOI
  18. [19]Schimke MM Marozin S Lepperdinger G. Patient-Specific Age: The other side of the coin in advanced mesenchymal stem cell therapy. Front Physiol. (2015) 6: 362. 10.3389/fphys.2015.00362 26696897 PMC4667069 · DOI
  19. [20]Charif N Li YY Targa L Zhang L Ye JS Li YP. Aging of bone marrow mesenchymal stromal/stem cells: implications on autologous regenerative medicine. Biomed Mater Eng. (2017) 28: S57– 63. 10.3233/BME-171624 28372278 · DOI
  20. [21]Van De Vyver M. Intrinsic mesenchymal stem cell dysfunction in diabetes mellitus: implications for autologous cell therapy. Stem Cells Dev. (2017) 26: 1042– 53. 10.1089/scd.2017.0025 28447876 · DOI
  21. [22]Yang YK. Aging of mesenchymal stem cells: implication in regenerative medicine. Regen Ther. (2018) 9: 120– 2. 10.1016/j.reth.2018.09.002 30525083 PMC6222976 · DOI
  22. [23]Khong SML Lee M Kosaric N Khong DM Dong Y Hopfner U. Single-cell transcriptomics of human mesenchymal stem cells reveal age-related cellular subpopulation depletion and impaired regenerative function. Stem Cells. (2019) 37: 240– 6. 10.1002/stem.2934 30412645 PMC10257472 · DOI
  23. [24]Wagner W Bork S Horn P Krunic D Walenda T Diehlmann A. Aging and replicative senescence have related effects on human stem and progenitor cells. PLoS ONE. (2009) 4: e5846. 10.1371/journal.pone.0005846 19513108 PMC2688074 · DOI
  24. [25]Block TJ Marinkovic M Tran ON Gonzalez AO Marshall A Dean DD. Restoring the quantity and quality of elderly human mesenchymal stem cells for autologous cell-based therapies. Stem Cell Res Ther. (2017) 8: 239. 10.1186/s13287-017-0688-x 29078802 PMC5658952 · DOI
  25. [26]Zhou S Greenberger JS Epperly MW Goff JP Adler C Leboff MS. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell. (2008) 7: 335– 43. 10.1111/j.1474-9726.2008.00377.x 18248663 PMC2398731 · DOI
  26. [27]Mareschi K Ferrero I Rustichelli D Aschero S Gammaitoni L Aglietta M. Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J Cell Biochem. (2006) 97: 744– 54. 10.1002/jcb.20681 16229018 · DOI
  27. [28]Laschober GT Brunauer R Jamnig A Singh S Hafen U Fehrer C. Age-specific changes of mesenchymal stem cells are paralleled by upregulation of CD106 expression as a response to an inflammatory environment. Rejuvenation Res. (2011) 14: 119– 31. 10.1089/rej.2010.1077 21214384 · DOI
  28. [29]Stolzing A Jones E Mcgonagle D Scutt A. Age-related changes in human bone marrow-derived mesenchymal stem cells: consequences for cell therapies. Mech Ageing Dev. (2008) 129: 163– 73. 10.1016/j.mad.2007.12.002 18241911 · DOI · Paper page
  29. [30]Mendes SC Tibbe JM Veenhof M Bakker K Both S Platenburg PP. Bone tissue-engineered implants using human bone marrow stromal cells: effect of culture conditions and donor age. Tissue Eng. (2002) 8: 911– 20. 10.1089/107632702320934010 12542937 · DOI
  30. [31]D'ippolito G Schiller PC Ricordi C Roos BA Howard GA. Age-related osteogenic potential of mesenchymal stromal stem cells from human vertebral bone marrow. J Bone Miner Res. (1999) 14: 1115– 22. 10.1359/jbmr.1999.14.7.1115 10404011 · DOI
  31. [32]Prall WC Saller MM Scheumaier A Tucholski T Taha S Bocker W. Proliferative and osteogenic differentiation capacity of mesenchymal stromal cells: influence of harvesting site and donor age. Injury. (2018) 49: 1504– 12. 10.1016/j.injury.2018.06.024 29941285 · DOI
  32. [34]Fan M Chen W Liu W Du GQ Jiang SL Tian WC. The effect of age on the efficacy of human mesenchymal stem cell transplantation after a myocardial infarction. Rejuvenation Res. (2010) 13: 429– 38. 10.1089/rej.2009.0986 20583954 · DOI
  33. [35]De Witte SFH Lambert EE Merino A Strini T Douben H O'flynn L. Aging of bone marrow- and umbilical cord-derived mesenchymal stromal cells during expansion. Cytotherapy. (2017) 19: 798– 807. 10.1016/j.jcyt.2017.03.071 28462821 · DOI
  34. [36]Oja S Komulainen P Penttila A Nystedt J Korhonen M. Automated image analysis detects aging in clinical-grade mesenchymal stromal cell cultures. Stem Cell Res Ther. (2018) 9: 6. 10.1186/s13287-017-0740-x 29321040 PMC5763576 · DOI
  35. [37]Bonab MM Alimoghaddam K Talebian F Ghaffari SH Ghavamzadeh A Nikbin B. Aging of mesenchymal stem cell in vitro. BMC Cell Biol. (2006) 7: 14. 10.1186/1471-2121-7-14 16529651 PMC1435883 · DOI
  36. [38]Schallmoser K Bartmann C Rohde E Bork S Guelly C Obenauf AC. Replicative senescence-associated gene expression changes in mesenchymal stromal cells are similar under different culture conditions. Haematologica. (2010) 95: 867– 74. 10.3324/haematol.2009.011692 20053868 PMC2878782 · DOI
  37. [39]Yin Y Wu RX He XT Xu XY Wang J Chen FM. Influences of age-related changes in mesenchymal stem cells on macrophages during in-vitro culture. Stem Cell Res Ther. (2017) 8: 153. 10.1186/s13287-017-0608-0 28646912 PMC5483296 · DOI
  38. [40]Ma Y Qi M An Y Zhang L Yang R Doro DH. Autophagy controls mesenchymal stem cell properties and senescence during bone aging. Aging Cell. (2018) 17. 10.1111/acel.12709. [Epub ahead of print]. 29210174 PMC5770781 · DOI
  39. [41]Moerman EJ Teng K Lipschitz DA Lecka-Czernik B. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell. (2004) 3: 379– 89. 10.1111/j.1474-9728.2004.00127.x 15569355 PMC1850101 · DOI
  40. [42]Kajkenova O Lecka-Czernik B Gubrij I Hauser SP Takahashi K Parfitt AM. Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia. J Bone Miner Res. (1997) 12: 1772– 9. 10.1359/jbmr.1997.12.11.1772 9383681 · DOI
  41. [43]Chen TL. Inhibition of growth and differentiation of osteoprogenitors in mouse bone marrow stromal cell cultures by increased donor age and glucocorticoid treatment. Bone. (2004) 35: 83– 95. 10.1016/j.bone.2004.03.019 15207744 · DOI
  42. [44]Kretlow JD Jin YQ Liu W Zhang WJ Hong TH Zhou G. Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells. BMC Cell Biol. (2008) 9: 60. 10.1186/1471-2121-9-60 18957087 PMC2584028 · DOI · Paper page
  43. [45]Katsara O Mahaira LG Iliopoulou EG Moustaki A Antsaklis A Loutradis D. Effects of donor age, gender, and in vitro cellular aging on the phenotypic, functional, and molecular characteristics of mouse bone marrow-derived mesenchymal stem cells. Stem Cells Dev. (2011) 20: 1549– 61. 10.1089/scd.2010.0280 21204633 · DOI
  44. [46]Wu LW Wang YL Christensen JM Khalifian S Schneeberger S Raimondi G. Donor age negatively affects the immunoregulatory properties of both adipose and bone marrow derived mesenchymal stem cells. Transpl Immunol. (2014) 30: 122– 7. 10.1016/j.trim.2014.03.001 24632513 · DOI
  45. [47]Santos LF Singulani MP Stringhetta-Garcia CT Oliveira SHP Chaves-Neto AH Dornelles RCM. Oxytocin effects on osteoblastic differentiation of Bone Marrow Mesenchymal Stem Cells from adult and aging female Wistar rats. Exp Gerontol. (2018) 113: 58– 63. 10.1016/j.exger.2018.09.023 30267870 · DOI
  46. [48]Geissler S Textor M Kuhnisch J Konnig D Klein O Ode A. Functional comparison of chronological and in vitro aging: differential role of the cytoskeleton and mitochondria in mesenchymal stromal cells. PLoS ONE. (2012) 7: e52700. 10.1371/journal.pone.0052700 23285157 PMC3532360 · DOI
  47. [49]Truong NC Bui KH Van Pham P. Characterization of senescence of human adipose-derived stem cells after long-term expansion. Adv Exp Med Biol. (2018) 1084: 109– 28. 10.1007/5584_2018_235 30242785 · DOI
  48. [50]Khanh VC Zulkifli AF Tokunaga C Yamashita T Hiramatsu Y Ohneda O. Aging impairs beige adipocyte differentiation of mesenchymal stem cells via the reduced expression of Sirtuin 1. Biochem Biophys Res Commun. (2018) 500: 682– 90. 10.1016/j.bbrc.2018.04.136 29678576 · DOI · Paper page
  49. [51]Liu M Lei H Dong P Fu X Yang Z Yang Y. Adipose-derived mesenchymal stem cells from the elderly exhibit decreased migration and differentiation abilities with senescent properties. Cell Transplant. (2017) 26: 1505– 19. 10.1177/0963689717721221 29113467 PMC5680952 · DOI
  50. [52]Efimenko A Dzhoyashvili N Kalinina N Kochegura T Akchurin R Tkachuk V. Adipose-derived mesenchymal stromal cells from aged patients with coronary artery disease keep mesenchymal stromal cell properties but exhibit characteristics of aging and have impaired angiogenic potential. Stem Cells Transl Med. (2014) 3: 32– 41. 10.5966/sctm.2013-0014 24353175 PMC3902283 · DOI
  51. [53]Kawagishi-Hotta M Hasegawa S Igarashi T Yamada T Takahashi M Numata S. Enhancement of individual differences in proliferation and differentiation potentials of aged human adipose-derived stem cells. Regen Ther. (2017) 6: 29– 40. 10.1016/j.reth.2016.12.004 30271837 PMC6134902 · DOI
  52. [54]Wiese DM Ruttan CC Wood CA Ford BN Braid LR. Accumulating transcriptome drift precedes cell aging in human umbilical cord-derived mesenchymal stromal cells serially cultured to replicative senescence. Stem Cells Transl Med. (2019) 8: 945– 58. 10.1002/sctm.18-0246 30924318 PMC6708062 · DOI
  53. [55]Davies LC Alm JJ Heldring N Moll G Gavin C Batsis I. Type 1 diabetes mellitus donor mesenchymal stromal cells exhibit comparable potency to healthy controls in vitro. Stem Cells Transl Med. (2016) 5: 1485– 95. 10.5966/sctm.2015-0272 27412884 PMC5070499 · DOI
  54. [56]Yaochite JN De Lima KW Caliari-Oliveira C Palma PV Couri CE Simoes BP. Multipotent mesenchymal stromal cells from patients with newly diagnosed type 1 diabetes mellitus exhibit preserved in vitro and in vivo immunomodulatory properties. Stem Cell Res Ther. (2016) 7: 14. 10.1186/s13287-015-0261-4 26781648 PMC4861132 · DOI
  55. [57]Brewster L Robinson S Wang R Griffiths S Li H Peister A. (2017). Expansion and angiogenic potential of mesenchymal stem cells from patients with critical limb ischemia. J Vasc Surg. 65, 826– 38 e821. 10.1016/j.jvs.2015.02.061 26921003 PMC4996777 · DOI
  56. [58]Acosta L Hmadcha A Escacena N Perez-Camacho I De La Cuesta A Ruiz-Salmeron R. Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity. Diabetes. (2013) 62: 4266– 9. 10.2337/db13-0896 24043757 PMC3837061 · DOI
  57. [59]Capilla-Gonzalez V Lopez-Beas J Escacena N Aguilera Y De La Cuesta A Ruiz-Salmeron R. PDGF restores the defective phenotype of adipose-derived mesenchymal stromal cells from diabetic patients. Mol Ther. (2018) 26: 2696– 709. 10.1016/j.ymthe.2018.08.011 30195725 PMC6224797 · DOI
  58. [60]Soria-Juan B Escacena N Capilla-González V Aguilera Y Llanos L Tejedo JR. Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus. Front Immunol. (2019) 10: 1151. 10.3389/fimmu.2019.01151 31231366 PMC6558400 · DOI
  59. [61]Dentelli P Barale C Togliatto G Trombetta A Olgasi C Gili M. A diabetic milieu promotes OCT4 and NANOG production in human visceral-derived adipose stem cells. Diabetologia. (2013) 56: 173– 84. 10.1007/s00125-012-2734-7 23064289 · DOI
  60. [62]Nawrocka D Kornicka K Szydlarska J Marycz K Basic fibroblast growth factor inhibits apoptosis and promotes proliferation of adipose-derived mesenchymal stromal cells isolated from patients with type 2 diabetes by reducing cellular oxidative stress. Oxid Med Cell Longev. (2017) 2017: 3027109 10.1155/2017/1083618 28168007 PMC5267085 · DOI
  61. [63]Kizilay Mancini O Shum-Tim D Stochaj U Correa JA Colmegna I. Age, atherosclerosis and type 2 diabetes reduce human mesenchymal stromal cell-mediated T-cell suppression. Stem Cell Res Ther. (2015) 6: 140. 10.1186/s13287-015-0127-9 26253429 PMC4529693 · DOI
  62. [64]Mangialardi G Katare R Oikawa A Meloni M Reni C Emanueli C. Diabetes causes bone marrow endothelial barrier dysfunction by activation of the RhoA-Rho-associated kinase signaling pathway. Arterioscler Thromb Vasc Biol. (2013) 33: 555– 64. 10.1161/ATVBAHA.112.300424 23307872 PMC3616369 · DOI
  63. [65]Oikawa A Siragusa M Quaini F Mangialardi G Katare RG Caporali A. Diabetes mellitus induces bone marrow microangiopathy. Arterioscler Thromb Vasc Biol. (2010) 30: 498– 508. 10.1161/ATVBAHA.109.200154 20042708 PMC3548136 · DOI
  64. [66]Reinke S Geissler S Taylor WR Schmidt-Bleek K Juelke K Schwachmeyer V. Terminally differentiated CD8(+) T cells negatively affect bone regeneration in humans. Sci Transl Med. (2013) 5: 177ra136. 10.1126/scitranslmed.3004754 23515078 · DOI
  65. [67]Rakow A Schoon J Dienelt A John T Textor M Duda G. Influence of particulate and dissociated metal-on-metal hip endoprosthesis wear on mesenchymal stromal cells in vivo and in vitro. Biomaterials. (2016) 98: 31– 40. 10.1016/j.biomaterials.2016.04.023 27179133 · DOI
  66. [68]Schoon J Geissler S Traeger J Luch A Tentschert J Perino G. Multi-elemental nanoparticle exposure after tantalum component failure in hip arthroplasty: in-depth analysis of a single case. Nanomedicine. (2017) 13: 2415– 23. 10.1016/j.nano.2017.08.004 28821464 · DOI
  67. [69]Dominici M Le Blanc K Mueller I Slaper-Cortenbach I Marini F Krause D. Minimal criteria for defining multipotent mesenchymal stromal cells. Int Soc Cell Ther Posit Statem Cytother. (2006) 8: 315– 7. 10.1080/14653240600855905 16923606 · DOI · Paper page
  68. [70]Schubert M Lindgreen S Orlando L. AdapterRemoval v2: rapid adapter trimming, identification, and read merging. BMC Res Notes. (2016) 9: 88. 10.1186/s13104-016-1900-2 26868221 PMC4751634 · DOI
  69. [71]Langmead B Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. (2012) 9: 357– 9. 10.1038/nmeth.1923 22388286 PMC3322381 · DOI · Paper page
  70. [72]Kim D Pertea G Trapnell C Pimentel H Kelley R Salzberg SL. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. (2013) 14: R36. 10.1186/gb-2013-14-4-r36 23618408 PMC4053844 · DOI · Paper page
  71. [73]Liao Y Smyth GK Shi W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. (2013) 41: e108. 10.1093/nar/gkt214 23558742 PMC3664803 · DOI · Paper page
  72. [74]Love MI Huber W Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. (2014) 15: 550. 10.1186/s13059-014-0550-8 25516281 PMC4302049 · DOI · Paper page
  73. [75]Yu G Wang LG Han Y He QY. clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. (2012) 16: 284– 7. 10.1089/omi.2011.0118 22455463 PMC3339379 · DOI · Paper page
  74. [76]Walter W Sanchez-Cabo F Ricote M. GOplot: an R package for visually combining expression data with functional analysis. Bioinformatics. (2015) 31: 2912– 4. 10.1093/bioinformatics/btv300 25964631 · DOI
  75. [77]Geissler S Textor M Schmidt-Bleek K Klein O Thiele M Ellinghaus A. In serum veritas-in serum sanitas? Cell non-autonomous aging compromises differentiation and survival of mesenchymal stromal cells via the oxidative stress pathway. Cell Death Dis. (2013) 4: e970. 10.1038/cddis.2013.501 24357801 PMC3877568 · DOI
  76. [78]Ode A Schoon J Kurtz A Gaetjen M Ode JE Geissler S. CD73/5'-ecto-nucleotidase acts as a regulatory factor in osteo-/chondrogenic differentiation of mechanically stimulated mesenchymal stromal cells. Eur Cell Mater. (2013) 25: 37– 47. 10.22203/eCM.v025a03 23300031 · DOI
  77. [79]Zickler D Luecht C Willy K Chen L Witowski J Girndt M. Tumour necrosis factor-alpha in uraemic serum promotes osteoblastic transition and calcification of vascular smooth muscle cells via extracellular signal-regulated kinases and activator protein 1/c-FOS-mediated induction of interleukin 6 expression. Nephrol Dial Transplant. (2018) 33: 574– 85. 10.1093/ndt/gfx316 29228352 · DOI
  78. [80]Flemming A Schallmoser K Strunk D Stolk M Volk HD Seifert M. Immunomodulative efficacy of bone marrow-derived mesenchymal stem cells cultured in human platelet lysate. J Clin Immunol. (2011) 31: 1143– 56. 10.1007/s10875-011-9581-z 21887517 · DOI
  79. [81]Catar R Witowski J Zhu N Lucht C Derrac Soria A Uceda Fernandez J. IL-6 trans-signaling links inflammation with angiogenesis in the peritoneal membrane. J Am Soc Nephrol. (2016) 28: 1188– 99. 10.1681/ASN.2015101169 27837150 PMC5373439 · DOI
  80. [82]Yang YK Ogando CR Wang See C Chang TY Barabino GA. Changes in phenotype and differentiation potential of human mesenchymal stem cells aging in vitro. Stem Cell Res Ther. (2018) 9: 131. 10.1186/s13287-018-0876-3 29751774 PMC5948736 · DOI
  81. [83]Na T Liu J Zhang K Ding M Yuan BZ. The notch signaling regulates CD105 expression, osteogenic differentiation and immunomodulation of human umbilical cord mesenchymal stem cells. PLoS ONE. (2015) 10: e0118168. 10.1371/journal.pone.0118168 25692676 PMC4334899 · DOI
  82. [84]Pittenger MF Mackay AM Beck SC Jaiswal RK Douglas R Mosca JD. Multilineage potential of adult human mesenchymal stem cells. Science. (1999) 284: 143– 7. 10.1126/science.284.5411.143 10102814 · DOI · Paper page
  83. [85]Galipeau J Krampera M Barrett J Dazzi F Deans RJ Debruijn J. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials. Cytotherapy. (2016) 18: 151– 9. 10.1016/j.jcyt.2015.11.008 26724220 PMC4745114 · DOI
  84. [86]Chinnadurai R Rajan D Qayed M Arafat D Garcia M Liu Y. Potency analysis of mesenchymal stromal cells using a combinatorial assay matrix approach. Cell Rep. (2018) 22: 2504– 17. 10.1016/j.celrep.2018.02.013 29490284 PMC5855117 · DOI
  85. [87]Ankrum JA Ong JF Karp JM Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. (2014) 32: 252– 60. 10.1038/nbt.2816 24561556 PMC4320647 · DOI
  86. [88]Dimmeler S Ding S Rando TA Trounson A. Translational strategies and challenges in regenerative medicine. Nat Med. (2014) 20: 814– 21. 10.1038/nm.3627 25100527 · DOI · Paper page
  87. [89]Viswanathan S Keating A Deans R Hematti P Prockop D Stroncek DF. Soliciting strategies for developing cell-based reference materials to advance mesenchymal stromal cell research and clinical translation. Stem Cells Dev. (2014) 23: 1157– 67. 10.1089/scd.2013.0591 24422625 PMC4027980 · DOI
  88. [90]Caplan AI. The mesengenic process. Clin Plast Surg. (1994) 21: 429– 35. 7924141
  89. [91]Fehrer C Lepperdinger G. Mesenchymal stem cell aging. Exp Gerontol. (2005) 40: 926– 30. 10.1016/j.exger.2005.07.006 16125890 · DOI
  90. [92]Das R Roosloot R Van Pel M Schepers K Driessen M Fibbe WE. Preparing for cell culture scale-out: establishing parity of bioreactor- and flask-expanded mesenchymal stromal cell cultures. J Transl Med. (2019) 17: 241. 10.1186/s12967-019-1989-x 31340829 PMC6657181 · DOI
  91. [93]Pasumarthy KK Doni Jayavelu N Kilpinen L Andrus C Battle SL Korhonen M. Methylome analysis of human bone marrow MSCs reveals extensive age- and culture-induced changes at distal regulatory elements. Stem Cell Rep. (2017) 9: 999– 1015. 10.1016/j.stemcr.2017.07.018 28844656 PMC5599244 · DOI
  92. [94]Mueller SM Glowacki J. Age-related decline in the osteogenic potential of human bone marrow cells cultured in three-dimensional collagen sponges. J Cell Biochem. (2001) 82: 583– 90. 10.1002/jcb.1174 11500936 · DOI
  93. [95]Doorn J Moll G Le Blanc K Van Blitterswijk C De Boer J. Therapeutic applications of mesenchymal stromal cells: paracrine effects and potential improvements. Tissue Eng Part B Rev. (2012) 18: 101– 15. 10.1089/ten.teb.2011.0488 21995703 · DOI
  94. [96]Ferreira JR Teixeira GQ Santos SG Barbosa MA Almeida-Porada G Goncalves RM. Mesenchymal stromal cell secretome: influencing therapeutic potential by cellular pre-conditioning. Front Immunol. (2018) 9: 2837. 10.3389/fimmu.2018.02837 30564236 PMC6288292 · DOI · Paper page
  95. [97]Lepperdinger G. Inflammation and mesenchymal stem cell aging. Curr Opin Immunol. (2011) 23: 518– 24. 10.1016/j.coi.2011.05.007 21703839 PMC3167021 · DOI
  96. [98]Menard C Dulong J Roulois D Hebraud B Verdiere L Pangault C. Integrated transcriptomic, phenotypic, and functional study reveals tissue-specific immune properties of mesenchymal stromal cells. Stem Cells. (2019). 10.1002/stem.3077. [Epub ahead of print]. 31502731 · DOI
  97. [99]Erhard F Halenius A Zimmermann C L'hernault A Kowalewski DJ Weekes MP. Improved Ribo-seq enables identification of cryptic translation events. Nat Methods. (2018) 15: 363– 6. 10.1038/nmeth.4631 29529017 PMC6152898 · DOI

Authors
Andrzejewska, A., Catar, R., Schoon, J., Qazi, T. H., Sass, F. A., Jacobi, D., Blankenstein, A., Reinke, S., Krüger, D., Streitz, M., Schlickeiser, S., Richter, S., Souidi, N., Beez, C., Kamhieh-Milz, J., Krüger, U., Zemojtel, T., Jürchott, K., Strunk, D., Reinke, P., Duda, G., Moll, G., & Geissler, S.
Affiliations
  • Humboldt-Universität zu Berlin (DE)
  • Paracelsus Medical University (AT)
Corresponding author
  • Moll, Guido
  • Geissler, Sven
ORCID
Venue
Frontiers in Immunology
Publisher
Frontiers Media SA
Published
2019-11-08
Volume
10
Pages
2474-2474
ISSN
1664-3224 (ISSN-L)
DOI
10.3389/fimmu.2019.02474
PMC
PMC6857652
OpenAlex
W2985027132
Cited by
89
References
103
Citations by year
2026: 7 · 2025: 7 · 2024: 10 · 2023: 21 · 2022: 17 · 2021: 16 · 2020: 11
FWCI
6.03
Type
journal article
Language
en
Open access
Licence
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Refubium (Universitätsbibliothek der Freien Universität Berlin) (submittedVersion, cc-by)
  • Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver (cc-by)
Funders
  • Deutsche Forschungsgemeinschaft (FOR2165, GE2512/2-2, GSC203)
  • Bundesministerium für Bildung, Wissenschaft, Forschung und Technologie (01EC1402B)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
  • Health Sciences › Medicine › Urology › Periodontal Regeneration and Treatments
Keywords
bone marrow-derived stromal cells, mesenchymal stem cells, donor age, comorbidities, in vitro aging, biobanking, cell expansion, multilineage differentiation, gene expression profiles, elderly donors, inflammatory cytokines
MeSH terms
Adult, Aged, Aging, Cell Differentiation, Cells, Cultured, Humans, Osteogenesis, Phenotype, Tissue Donors, Comorbidity, Immunophenotyping, Cellular Senescence, Biological Specimen Banks, Cell Lineage, Chondrogenesis, Cell Proliferation, Adipogenesis, Adult Stem Cells, Transcriptome, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review